Aurinia Pharmaceuticals Inc
Suletud
SektorTervishoid
18.63 3.9
Ülevaade
Aktsiahinna muutus
24h
Min
17.8
Max
19.19
Sissetulek | -176M 34M |
|---|---|
Müük | 591K 78M |
P/E Sektori keskmine | 8.051 50.958 |
Aktsiakasum | 0.25 |
Kasumimarginaal | 44.212 |
Töötajad | 128 |
EBITDA | 2.7M 50M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | -12.36% downside |
Järgmine tulemuste avaldamine | 30. juuli 2026 |
|---|
Turukapital | 187M 2.2B |
|---|---|
Eelmine avamishind | 14.73 |
Eelmine sulgemishind | 18.63 |
Uudiste sentiment
By Acuity
50%
50%
146 / 342 Pingereas Healthcare
Aurinia Pharmaceuticals Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
